{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:53:16Z","timestamp":1791269596322,"version":"4.1.0"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100013105","name":"Shanghai Rising-Star Program","doi-asserted-by":"publisher","award":["23QA1408200"],"award-info":[{"award-number":["23QA1408200"]}],"id":[{"id":"10.13039\/501100013105","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03424-1","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:37:31Z","timestamp":1791268651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population"],"prefix":"10.1007","volume":"43","author":[{"given":"Zijie","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8738-0357","authenticated-orcid":false,"given":"Lingling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"issue":"1","key":"3424_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1) :17\u201348. . https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"3424_CR2","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1056\/NEJMcp2209151","volume":"388","author":"PF Pinsky","year":"2023","unstructured":"Pinsky PF, Parnes H. Screening for prostate cancer. Solomon CG. editor N Engl J Med. 2023;388(6) :1405\u201314. . https:\/\/doi.org\/10.1056\/NEJMcp2209151","journal-title":"editor N Engl J Med"},{"key":"3424_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, Van Den Bergh RCN, Briers E, Van Den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol"},{"key":"3424_CR4","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","volume":"333","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB. Prostate cancer: a review. JAMA. 2025;333:1433. https:\/\/doi.org\/10.1001\/jama.2025.0228.","journal-title":"JAMA"},{"key":"3424_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ucl.2025.09.001","volume":"53","author":"O Nativ","year":"2026","unstructured":"Nativ O, Reid G, Sadiq S, Cuvet M, Punnen S. Prostate cancer screening: Evolution, Challenges, and Future Directions. Urol Clin North Am. 2026;53:1\u201313. https:\/\/doi.org\/10.1016\/j.ucl.2025.09.001.","journal-title":"Urol Clin North Am"},{"key":"3424_CR6","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41585-022-00638-6","volume":"19","author":"H Van Poppel","year":"2022","unstructured":"Van Poppel H, Albreht T, Basu P, Hogenhout R, Collen S, Roobol M. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat Rev Urol. 2022;19:562\u201372. https:\/\/doi.org\/10.1038\/s41585-022-00638-6.","journal-title":"Nat Rev Urol"},{"key":"3424_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41585-019-0212-4","volume":"17","author":"A Stabile","year":"2020","unstructured":"Stabile A, Giganti F, Rosenkrantz AB, Taneja SS, Villeirs G, Gill IS, et al. Multiparametric MRI for prostate cancer diagnosis: current status and future directions. Nat Rev Urol. 2020;17:41\u201361. https:\/\/doi.org\/10.1038\/s41585-019-0212-4.","journal-title":"Nat Rev Urol"},{"key":"3424_CR8","doi-asserted-by":"publisher","unstructured":"Turkbey, B Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, PI-RADS-Prostate imaging reporting and data system version 2.1: 2019 update of prostateimaging reporting and data system version 210.1016\/j.eururo.2019.02.033https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033","DOI":"10.1016\/j.eururo.2019.02.033"},{"key":"3424_CR9","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.3390\/cancers15143682","volume":"15","author":"A \u017burowska","year":"2023","unstructured":"\u017burowska A, P\u0119ksa R, Bie\u0144kowski M, Skrobisz K, Sowa M, Matuszewski M, et al. Prostate Cancer and Its Mimics\u2014A. Pict Rev Cancers. 2023;15:3682. https:\/\/doi.org\/10.3390\/cancers15143682.","journal-title":"Pict Rev Cancers"},{"key":"3424_CR10","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1056\/NEJM199104253241702","volume":"324","author":"WJ Catalona","year":"1991","unstructured":"Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156\u201361. https:\/\/doi.org\/10.1056\/NEJM199104253241702.","journal-title":"N Engl J Med"},{"key":"3424_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.euf.2019.06.014","volume":"6","author":"M Maggi","year":"2020","unstructured":"Maggi M, Panebianco V, Mosca A, Salciccia S, Gentilucci A, Di Pierro G, et al. Prostate imaging reporting and data system 3 category cases at multiparametric magnetic resonance for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus. 2020;6:463\u201378. https:\/\/doi.org\/10.1016\/j.euf.2019.06.014.","journal-title":"Eur Urol Focus"},{"key":"3424_CR12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s11934-023-01187-0","volume":"24","author":"Z Kang","year":"2023","unstructured":"Kang Z, Margolis DJ, Wang S, Li Q, Song J, Wang L. Management strategy for prostate imaging reporting and data system category 3 lesions. Curr Urol Rep. 2023;24:561\u201370. https:\/\/doi.org\/10.1007\/s11934-023-01187-0.","journal-title":"Curr Urol Rep"},{"key":"3424_CR13","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1186\/s12885-025-14505-1","volume":"25","author":"Y Ahamed","year":"2025","unstructured":"Ahamed Y, Hossain M, Baral S, Al-Raiyan AU, Ashraf SB, Sun W. The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer. BMC Cancer. 2025;25:1264. https:\/\/doi.org\/10.1186\/s12885-025-14505-1.","journal-title":"BMC Cancer"},{"key":"3424_CR14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.4103\/1008-682X.126388","volume":"16","author":"A Minervini","year":"2014","unstructured":"Minervini A, Vittori G, Siena G, Carini M. Morbidity and psychological impact of prostate biopsy: the future calls for a change. Asian J Androl. 2014;16:415\u20137. https:\/\/doi.org\/10.4103\/1008-682X.126388.","journal-title":"Asian J Androl"},{"key":"3424_CR15","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.3390\/cancers15123110","volume":"15","author":"SO Oseni","year":"2023","unstructured":"Oseni SO, Naar C, Pavlovi\u0107 M, Asghar W, Hartmann JX, Fields GB, et al. The molecular basis and clinical consequences of chronic inflammation in prostatic diseases: prostatitis, benign prostatic hyperplasia, and prostate cancer. Cancers. 2023;15:3110. https:\/\/doi.org\/10.3390\/cancers15123110.","journal-title":"Cancers"},{"key":"3424_CR16","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41416-024-02762-z","volume":"131","author":"M Pujana-Vaquerizo","year":"2024","unstructured":"Pujana-Vaquerizo M, Bozal-Basterra L, Carracedo A. Metabolic adaptations in prostate cancer. Br J Cancer. 2024;131:1250\u201362. https:\/\/doi.org\/10.1038\/s41416-024-02762-z.","journal-title":"Br J Cancer"},{"key":"3424_CR17","doi-asserted-by":"publisher","first-page":"21694","DOI":"10.1002\/cam4.6728","volume":"12","author":"Q Yang","year":"2023","unstructured":"Yang Q, Li Q, Li N, Wang D, Niu S, Tang P, et al. Radiotranscriptomics identified new mRNAs and miRNA markers for distinguishing prostate cancer from benign prostatic hyperplasia. Cancer Med. 2023;12:21694\u2013708. https:\/\/doi.org\/10.1002\/cam4.6728.","journal-title":"Cancer Med"},{"key":"3424_CR18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40644-025-00938-1","volume":"25","author":"K Min","year":"2025","unstructured":"Min K, Lin Q, Qiu D. Precision medicine in prostate cancer: individualized treatment through radiomics, genomics, and biomarkers. Cancer Imaging. 2025;25:116. https:\/\/doi.org\/10.1186\/s40644-025-00938-1.","journal-title":"Cancer Imaging"},{"key":"3424_CR19","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3390\/biology13100762","volume":"13","author":"S Hachem","year":"2024","unstructured":"Hachem S, Yehya A, El Masri J, Mavingire N, Johnson JR, Dwead AM, et al. Contemporary update on clinical and experimental prostate cancer biomarkers: a multi-omics-focused approach to detection and risk stratification. Biology. 2024;13:762. https:\/\/doi.org\/10.3390\/biology13100762.","journal-title":"Biology"},{"key":"3424_CR20","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1039\/D1LC00485A","volume":"21","author":"C-J Kim","year":"2021","unstructured":"Kim C-J, Dong L, Amend SR, Cho Y-K, Pienta KJ. The role of liquid biopsies in prostate cancer management. Lab Chip. 2021;21:3263\u201388. https:\/\/doi.org\/10.1039\/D1LC00485A.","journal-title":"Lab Chip"},{"key":"3424_CR21","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.3390\/cancers16172951","volume":"16","author":"A Antolin","year":"2024","unstructured":"Antolin A, Roson N, Mast R, Arce J, Almodovar R, Cortada R, et al. The role of radiomics in the prediction of clinically significant prostate cancer in the PI-RADS v2 and v2.1 era: a systematic review. Cancers. 2024;16:2951. https:\/\/doi.org\/10.3390\/cancers16172951.","journal-title":"Cancers"},{"key":"3424_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41391-023-00708-9","volume":"27","author":"F Ditonno","year":"2024","unstructured":"Ditonno F, Franco A, Manfredi C, Veccia A, Valerio M, Bukavina L, et al. Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET\/CT. Prostate Cancer Prostatic Dis. 2024;27:29\u201336. https:\/\/doi.org\/10.1038\/s41391-023-00708-9.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3424_CR23","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/cancers14071702","volume":"14","author":"SM Mutuku","year":"2022","unstructured":"Mutuku SM, Spotbeen X, Trim PJ, Snel MF, Butler LM, Swinnen JV. Unravelling prostate cancer heterogeneity using spatial approaches to lipidomics and transcriptomics. Cancers. 2022;14:1702. https:\/\/doi.org\/10.3390\/cancers14071702.","journal-title":"Cancers"},{"key":"3424_CR24","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41391-024-00852-w","volume":"27","author":"FB Denijs","year":"2024","unstructured":"Denijs FB, Van Harten MJ, Meenderink JJL, Leenen RCA, Remmers S, Venderbos LDF, et al. Risk calculators for the detection of prostate cancer: a systematic review. Prostate Cancer Prostatic Dis. 2024;27:544\u201357. https:\/\/doi.org\/10.1038\/s41391-024-00852-w.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3424_CR25","doi-asserted-by":"publisher","first-page":"893424","DOI":"10.3389\/fonc.2022.893424","volume":"12","author":"Z Wei","year":"2022","unstructured":"Wei Z, Han D, Zhang C, Wang S, Liu J, Chao F, et al. Deep learning-based multi-omics integration robustly predicts relapse in prostate cancer. Front Oncol. 2022;12:893424. https:\/\/doi.org\/10.3389\/fonc.2022.893424.","journal-title":"Front Oncol"},{"key":"3424_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000004995","author":"DW Lin","year":"2026","unstructured":"Lin DW, Carlsson S, Filson CP, Kim SK, Kirkby E, Konety BR, et al. Updates to Early Detection of Prostate Cancer: AUA\/SUO Guideline (2026). J Urol. 2026;215(5):491-501. https:\/\/doi.org\/10.1097\/JU.0000000000004995","journal-title":"J Urol"},{"key":"3424_CR27","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Prostate Cancer Early Detection. Version 2.2026. Accessed March 08, 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate_detection.pdf"},{"key":"3424_CR28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/pros.24840","volume":"85","author":"A Ayranci","year":"2025","unstructured":"Ayranci A, Caglar U, Yazili HB, Erdal FS, Erbin A, Sarilar O, et al. PSA density and lesion volume: key factors in avoiding unnecessary biopsies for PI-RADS 3 lesions. Prostate. 2025;85:385\u201390. https:\/\/doi.org\/10.1002\/pros.24840.","journal-title":"Prostate"},{"key":"3424_CR29","doi-asserted-by":"publisher","first-page":"e244258","DOI":"10.1001\/jamanetworkopen.2024.4258","volume":"7","author":"A Haj-Mirzaian","year":"2024","unstructured":"Haj-Mirzaian A, Burk KS, Lacson R, Glazer DI, Saini S, Kibel AS, et al. Magnetic resonance imaging, clinical, and biopsy findings in suspected prostate cancer: a systematic review and meta-analysis. JAMA Netw Open. 2024;7:e244258. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.4258.","journal-title":"JAMA Netw Open"},{"key":"3424_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.euo.2023.08.002","volume":"7","author":"S Wang","year":"2024","unstructured":"Wang S, Kozarek J, Russell R, Drescher M, Khan A, Kundra V, et al. Diagnostic performance of PSA density for detecting clinically significant prostate cancer in the era of MRI: a systematic review and meta-analysis. Eur Urol Oncol. 2024;7:189\u2013203. https:\/\/doi.org\/10.1016\/j.euo.2023.08.002.","journal-title":"Eur Urol Oncol"},{"key":"3424_CR31","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s12672-025-03402-5","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, Sun J, Xu D, Zhu H. Biproximate ellipsoid formula with transrectal ultrasound: a superior method for PSA density in gray zone prostate cancer detection. Discov Oncol. 2025;16:1583. https:\/\/doi.org\/10.1007\/s12672-025-03402-5.","journal-title":"Discov Oncol"},{"key":"3424_CR32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.eururo.2018.10.047","volume":"75","author":"PK-F Chiu","year":"2019","unstructured":"Chiu PK-F, Ng C-F, Semjonow A, Zhu Y, Vincendeau S, Houlgatte A, et al. A multicentre evaluation of the role of the prostate health index (PHI) in regions with differing prevalence of prostate cancer: adjustment of PHI reference ranges is needed for European and Asian settings. Eur Urol. 2019;75:558\u201361. https:\/\/doi.org\/10.1016\/j.eururo.2018.10.047.","journal-title":"Eur Urol"},{"key":"3424_CR33","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12885-026-15577-3","volume":"26","author":"X Zhong","year":"2026","unstructured":"Zhong X, Xiong Y, Yang F, Yang Y, Gong X, Wang S, et al. Prostate health index enhances prostate cancer management in chinese populations: evidence from the nation\u2019s large cohort and transnational multicohort harmonization. BMC Cancer. 2026;26:254\u201364. https:\/\/doi.org\/10.1186\/s12885-026-15577-3.","journal-title":"BMC Cancer"},{"key":"3424_CR34","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1007\/s00345-020-03585-2","volume":"39","author":"C Stephan","year":"2021","unstructured":"Stephan C, Jung K, Lein M, Rochow H, Friedersdorff F, Maxeiner A. PHI density prospectively improves prostate cancer detection. World J Urol. 2021;39:3273\u20139. https:\/\/doi.org\/10.1007\/s00345-020-03585-2.","journal-title":"World J Urol"},{"key":"3424_CR35","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s11255-022-03113-8","volume":"54","author":"H Chen","year":"2022","unstructured":"Chen H, Shi B, Wu Y, Qian Y, Zhou J, Zhang X, et al. The modified prostate health index (PHI) outperforms PHI density in the detection of clinical prostate cancer within the PSA grey zone. Int Urol Nephrol. 2022;54:749\u201356. https:\/\/doi.org\/10.1007\/s11255-022-03113-8.","journal-title":"Int Urol Nephrol"},{"key":"3424_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41391-024-00840-0","volume":"28","author":"HS Robinson","year":"2025","unstructured":"Robinson HS, Lee SS, Barocas DA, Tosoian JJ. Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer. Prostate Cancer Prostatic Dis. 2025;28:45\u201355. https:\/\/doi.org\/10.1038\/s41391-024-00840-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3424_CR37","doi-asserted-by":"publisher","first-page":"366e1","DOI":"10.1016\/j.urolonc.2020.11.001","volume":"39","author":"C Mi","year":"2021","unstructured":"Mi C, Bai L, Yang Y, Duan J, Gao L. 4Kscore diagnostic value in patients with high-grade prostate cancer using cutoff values of 7.5% to 10%: a meta-analysis. Urol Oncol Semin Orig Investig. 2021;39:366e1. https:\/\/doi.org\/10.1016\/j.urolonc.2020.11.001.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"3424_CR38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.eururo.2024.04.037","volume":"86","author":"A Josefsson","year":"2024","unstructured":"Josefsson A, M\u00e5nsson M, Kohestani K, Spyratou V, Wallstr\u00f6m J, Hellstr\u00f6m M, et al. Performance of 4Kscore as a reflex test to prostate-specific antigen in the G\u00d6TEBORG-2 prostate cancer screening trial. Eur Urol. 2024;86:223\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.037.","journal-title":"Eur Urol"},{"key":"3424_CR39","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1001\/jama.2024.3841","volume":"331","author":"A Auvinen","year":"2024","unstructured":"Auvinen A, Tammela TLJ, Mirtti T, Lilja H, Tolonen T, Kentt\u00e4mies A, et al. Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial. JAMA. 2024;331:1452. https:\/\/doi.org\/10.1001\/jama.2024.3841.","journal-title":"JAMA"},{"key":"3424_CR40","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","volume":"384","author":"FH Schr\u00f6der","year":"2014","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027-2035 https:\/\/doi.org\/10.1016\/S0140-6736(14)60525-0","journal-title":"Lancet"},{"key":"3424_CR41","doi-asserted-by":"publisher","unstructured":"Wang B, Benidir T, Dortche K, Bullen J, Lone Z, Abdallah N, et al. IsoPSA density improves risk stratification and biopsy decision-making for clinically significant prostate cancer. Urol Oncol Semin Orig Investig. 2026;44. https:\/\/doi.org\/10.1016\/j.urolonc.2025.09.001. :70.e1-70.e9.","DOI":"10.1016\/j.urolonc.2025.09.001"},{"key":"3424_CR42","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.eururo.2017.03.025","volume":"72","author":"EA Klein","year":"2017","unstructured":"Klein EA, Chait A, Hafron JM, Kernen KM, Manickam K, Stephenson AJ, et al. The single-parameter, structure-based IsoPSA assay demonstrates improved diagnostic accuracy for detection of any prostate cancer and high-grade prostate cancer compared to a concentration-based assay of total prostate-specific antigen: a preliminary report. Eur Urol. 2017;72:942\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2017.03.025.","journal-title":"Eur Urol"},{"key":"3424_CR43","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.urolonc.2022.06.002","volume":"40","author":"EA Klein","year":"2022","unstructured":"Klein EA, Partin A, Lotan Y, Baniel J, Dineen M, Hafron J, et al. Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: a prospective, multicenter study. Urol Oncol Semin Orig Investig. 2022;40:408. https:\/\/doi.org\/10.1016\/j.urolonc.2022.06.002.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"3424_CR44","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.urology.2023.01.037","volume":"175","author":"JM Scovell","year":"2023","unstructured":"Scovell JM, Stovsky M, Partin A, Lotan Y, Baniel J, Dineen M, et al. IsoPSA performance characteristics are unaffected by 5-alpha reductase inhibitors or alpha-blockers: results from the IsoPSA validation study. Urology. 2023;175:132\u20136. https:\/\/doi.org\/10.1016\/j.urology.2023.01.037.","journal-title":"Urology"},{"key":"3424_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eururo.2019.02.033","volume":"23","author":"A Kennedy","year":"2024","unstructured":"Kennedy A, Hafron J. Incorporation of IsoPSA into clinical practice in the management of elevated prostate-specific antigen based on current guidelines. Rev Urol. 2024;23(3):e63-e70. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033","journal-title":"Rev Urol"},{"key":"3424_CR46","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/JU.0000000000000293","volume":"202","author":"A Haese","year":"2019","unstructured":"Haese A, Trooskens G, Steyaert S, Hessels D, Brawer M, Vlaeminck-Guillem V, et al. Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer before initial prostate biopsy. J Urol. 2019;202:256\u201363. https:\/\/doi.org\/10.1097\/JU.0000000000000293.","journal-title":"J Urol"},{"key":"3424_CR47","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41391-021-00367-8","volume":"24","author":"RJ Hendriks","year":"2021","unstructured":"Hendriks RJ, Van Der Leest MMG, Isra\u00ebl B, Hannink G, YantiSetiasti A, Cornel EB, et al. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-na\u00efve men. Prostate Cancer Prostatic Dis. 2021;24:1110\u20139. https:\/\/doi.org\/10.1038\/s41391-021-00367-8.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3424_CR48","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41391-022-00538-1","volume":"25","author":"R Sari Motlagh","year":"2022","unstructured":"Sari Motlagh R, Yanagisawa T, Kawada T, Laukhtina E, Rajwa P, Aydh A, et al. Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis. Prostate Cancer Prostatic Dis. 2022;25:187\u201398. https:\/\/doi.org\/10.1038\/s41391-022-00538-1.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3424_CR49","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/JU.0000000000001430","volume":"205","author":"JJ Tosoian","year":"2021","unstructured":"Tosoian JJ, Trock BJ, Morgan TM, Salami SS, Tomlins SA, Spratt DE, et al. Use of the MyProstateScore test to rule out clinically significant cancer: validation of a straightforward clinical testing approach. J Urol. 2021;205:732\u20139. https:\/\/doi.org\/10.1097\/JU.0000000000001430.","journal-title":"J Urol"},{"key":"3424_CR50","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.urology.2021.11.033","volume":"164","author":"JJ Tosoian","year":"2022","unstructured":"Tosoian JJ, Singhal U, Davenport MS, Wei JT, Montgomery JS, George AK, et al. Urinary MyProstateScore (MPS) to rule out clinically-significant cancer in men with equivocal (PI-RADS 3) multiparametric MRI: addressing an unmet clinical need. Urology. 2022;164:184\u201390. https:\/\/doi.org\/10.1016\/j.urology.2021.11.033.","journal-title":"Urology"},{"key":"3424_CR51","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1001\/jamaoncol.2024.0455","volume":"10","author":"JJ Tosoian","year":"2024","unstructured":"Tosoian JJ, Zhang Y, Xiao L, Xie C, Samora NL, Niknafs YS, et al. Development and validation of an 18-gene urine test for high-grade prostate cancer. JAMA Oncol. 2024;10:726\u201336. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0455.","journal-title":"JAMA Oncol"},{"key":"3424_CR52","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/JU.0000000000004421","volume":"213","author":"JJ Tosoian","year":"2025","unstructured":"Tosoian JJ, Zhang Y, Meyers JI, Heaton S, Siddiqui J, Xiao L, et al. Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non\u2013Digital Rectal Examination Urine. J Urol. 2025;213:581\u20139. https:\/\/doi.org\/10.1097\/JU.0000000000004421.","journal-title":"J Urol"},{"key":"3424_CR53","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41391-020-0237-z","volume":"23","author":"R Tutrone","year":"2020","unstructured":"Tutrone R, Donovan MJ, Torkler P, Tadigotla V, McLain T, Noerholm M, et al. Clinical utility of the exosome based ExoDx prostate(IntelliScore) EPI test in men presenting for initial biopsy with a PSA 2\u201310 ng\/mL. Prostate Cancer Prostatic Dis. 2020;23:607\u201314. . https:\/\/doi.org\/10.1038\/s41391-020-0237-z","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3424_CR54","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1001\/jamaoncol.2016.0097","volume":"2","author":"J McKiernan","year":"2016","unstructured":"McKiernan J, Donovan MJ, O\u2019Neill V, Bentink S, Noerholm M, Belzer S, et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2016;2:882. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0097.","journal-title":"JAMA Oncol"},{"key":"3424_CR55","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41391-021-00456-8","volume":"25","author":"E Margolis","year":"2022","unstructured":"Margolis E, Brown G, Partin A, Carter B, McKiernan J, Tutrone R, et al. Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) prostate intelliscore test in three independent prospective studies. Prostate Cancer Prostatic Dis. 2022;25:296\u2013301. https:\/\/doi.org\/10.1038\/s41391-021-00456-8.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3424_CR56","doi-asserted-by":"publisher","first-page":"716415","DOI":"10.3389\/fmolb.2021.716415","volume":"8","author":"L Yang","year":"2021","unstructured":"Yang L, Lu P, Yang X, Li K, Qu S. Annexin A3, a Calcium-Dependent Phospholipid-Binding Protein: Implication in Cancer. Front Mol Biosci. 2021;8:716415. https:\/\/doi.org\/10.3389\/fmolb.2021.716415.","journal-title":"Front Mol Biosci"},{"key":"3424_CR57","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.eururo.2008.01.001","volume":"54","author":"J K\u00f6llermann","year":"2008","unstructured":"K\u00f6llermann J, Schlomm T, Bang H, Schwall GP, Von Eichel-Streiber C, Simon R, et al. Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol. 2008;54:1314\u201323. https:\/\/doi.org\/10.1016\/j.eururo.2008.01.001.","journal-title":"Eur Urol"},{"key":"3424_CR58","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1158\/0008-5472.CAN-07-2559","volume":"68","author":"TR Graham","year":"2008","unstructured":"Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, et al. Insulin-like growth factor-I\u2013dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2008;68:2479\u201388. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2559.","journal-title":"Cancer Res"},{"key":"3424_CR59","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.juro.2008.08.119","volume":"181","author":"M Schostak","year":"2009","unstructured":"Schostak M, Schwall GP, Poznanovi\u0107 S, Groebe K, M\u00fcller M, Messinger D, et al. Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol. 2009;181:343\u201353. https:\/\/doi.org\/10.1016\/j.juro.2008.08.119.","journal-title":"J Urol"},{"key":"3424_CR60","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1524-475X.2011.00753.x","volume":"20","author":"AI Chernyavsky","year":"2012","unstructured":"Chernyavsky AI, Kalantari-Dehaghi M, Phillips C, Marchenko S, Grando SA. SLURP-Novel cholinergic peptides SLURP \u2013\u20091 and \u2013\u20092 regulate epithelialization of cutaneous and oral wounds. Wound Repair Regen. 2012;20:103\u201313. https:\/\/doi.org\/10.1111\/j.1524-475X.2011.00753.x.","journal-title":"Wound Repair Regen"},{"key":"3424_CR61","doi-asserted-by":"publisher","first-page":"1365615","DOI":"10.3389\/fonc.2024.1365615","volume":"14","author":"T Yang","year":"2024","unstructured":"Yang T, Liu T, Lei T, Li T, Liu N, Zhang M. Unveiling the potential of SLURP1 protein as a biomarker for prostate cancer screening. Front Oncol. 2024;14:1365615. https:\/\/doi.org\/10.3389\/fonc.2024.1365615.","journal-title":"Front Oncol"},{"key":"3424_CR62","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/imj.12407","volume":"44","author":"C Pezaro","year":"2014","unstructured":"Pezaro C, Woo HH, Davis ID. Prostate cancer: measuring PSA. Intern Med J. 2014;44:433\u201340. https:\/\/doi.org\/10.1111\/imj.12407.","journal-title":"Intern Med J"},{"key":"3424_CR63","doi-asserted-by":"publisher","first-page":"17368","DOI":"10.1021\/acs.analchem.5c01320","volume":"97","author":"Y-P Fan","year":"2025","unstructured":"Fan Y-P, Zhang Y-T, Zhang G, Ma L, Lv Y, Li J, et al. Proteomic profiling of urinary large extracellular vesicles for the diagnosis of prostate cancer. Anal Chem. 2025;97:17368\u201379. https:\/\/doi.org\/10.1021\/acs.analchem.5c01320.","journal-title":"Anal Chem"},{"key":"3424_CR64","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1158\/1078-0432.CCR-10-2410","volume":"17","author":"R Morgan","year":"2011","unstructured":"Morgan R, Boxall A, Bhatt A, Bailey M, Hindley R, Langley S, et al. Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer. Clin Cancer Res. 2011;17:1090\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2410.","journal-title":"Clin Cancer Res"},{"key":"3424_CR65","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1590\/1806-9282.63.07.656","volume":"63","author":"MID Rosa","year":"2017","unstructured":"Rosa MID, Dondossola ER, Alexandre MCM, Madeira K, Cardoso FDA, Grande AJ. Urinary EN-2 to predict prostate cancer: systematic review and meta-analysis. Rev Assoc M\u00e9dica Bras. 2017;63:656\u201361. https:\/\/doi.org\/10.1590\/1806-9282.63.07.656.","journal-title":"Rev Assoc M\u00e9dica Bras"},{"key":"3424_CR66","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.3390\/cancers13092102","volume":"13","author":"S Connell","year":"2021","unstructured":"Connell S, Mills R, Pandha H, Morgan R, Cooper C, Clark J, et al. Integration of urinary EN2 protein & cell-free RNA data in the development of a multivariable risk model for the detection of prostate cancer prior to biopsy. Cancers. 2021;13:2102. https:\/\/doi.org\/10.3390\/cancers13092102.","journal-title":"Cancers"},{"key":"3424_CR67","doi-asserted-by":"publisher","unstructured":"Ribeiro FR, Paulo P, Costa VL, Barros-Silva JD, Ramalho-Carvalho J, Jer\u00f3nimo C et al. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. Batra SK, editor. PLOS One. 2011;6:e22317. https:\/\/doi.org\/10.1371\/journal.pone.0022317","DOI":"10.1371\/journal.pone.0022317"},{"key":"3424_CR68","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1530\/ERC-20-0092","volume":"27","author":"M Volpert","year":"2020","unstructured":"Volpert M, Furic L, Hu J, O\u2019Connor AE, Rebello RJ, Keerthikumar S, et al. CRISP3 expression drives prostate cancer invasion and progression. Endocr Relat Cancer. 2020;27:415\u201330. https:\/\/doi.org\/10.1530\/ERC-20-0092.","journal-title":"Endocr Relat Cancer"},{"key":"3424_CR69","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jsbmb.2018.02.012","volume":"181","author":"BR Pathak","year":"2018","unstructured":"Pathak BR, Breed AA, Deshmukh P, Mahale SD. Androgen receptor mediated epigenetic regulation of CRISP3 promoter in prostate cancer cells. J Steroid Biochem Mol Biol. 2018;181:20\u20137. https:\/\/doi.org\/10.1016\/j.jsbmb.2018.02.012.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3424_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5935\/1676-2444.20210012","volume":"57","author":"ADL Carvalho","year":"2021","unstructured":"Carvalho ADL, Pinto SA, Santos WGD. CRISP3 glycoprotein: a good biomarker for prostate cancer? J Bras Patol Med Lab. 2021;57(1):1-7. https:\/\/doi.org\/10.5935\/1676-2444.20210012","journal-title":"J Bras Patol E Med Lab"},{"key":"3424_CR71","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/pros.20342","volume":"66","author":"A Bjartell","year":"2006","unstructured":"Bjartell A, Johansson R, Bj\u00f6rk T, Gadaleanu V, Lundwall \u00c5, Lilja H, et al. Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. Prostate. 2006;66:591\u2013603. https:\/\/doi.org\/10.1002\/pros.20342.","journal-title":"Prostate"},{"key":"3424_CR72","first-page":"281","volume":"22","author":"M Zhang","year":"2016","unstructured":"Zhang M, Chen L, Yuan Z, Yang Z, Li Y, Shan L, et al. Combined serum and EPS-urine proteomic analysis using iTRAQ technology for discovery of potential prostate cancer biomarkers. Discov Med. 2016;22:281\u201395.","journal-title":"Discov Med"},{"key":"3424_CR73","doi-asserted-by":"publisher","first-page":"15896","DOI":"10.1021\/acsnano.5c01564","volume":"19","author":"W Zeng","year":"2025","unstructured":"Zeng W, Zhang Y, Wang X, Wang S, Lin T, Su T, et al. Chemical Affinity Capture of Plasma Extracellular Vesicles Enables Efficient and Large-Scale Proteomic Identification of Prostate Cancer Biomarkers. ACS Nano. 2025;19:15896\u2013911. https:\/\/doi.org\/10.1021\/acsnano.5c01564.","journal-title":"ACS Nano"},{"key":"3424_CR74","doi-asserted-by":"publisher","first-page":"6214","DOI":"10.7150\/thno.55676","volume":"11","author":"J Song","year":"2021","unstructured":"Song J, Ma S, Sokoll LJ, Eguez RV, H\u00f6ti N, Zhang H, et al. A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer. Theranostics. 2021;11:6214\u201324. https:\/\/doi.org\/10.7150\/thno.55676.","journal-title":"Theranostics"},{"key":"3424_CR75","doi-asserted-by":"publisher","first-page":"411","DOI":"10.4111\/icu.2020.61.4.411","volume":"61","author":"HW Kang","year":"2020","unstructured":"Kang HW, Lee HY, Byun YJ, Jeong P, Yoon JS, Kim DH, et al. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone. Investig Clin Urol. 2020;61:411\u20138. https:\/\/doi.org\/10.4111\/icu.2020.61.4.411.","journal-title":"Investig Clin Urol"},{"key":"3424_CR76","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/cells15010083","volume":"15","author":"SM Yaghoubi","year":"2026","unstructured":"Yaghoubi SM, Zare E, Jafari Dargahlou S, Jafari M, Azimi M, Khoshnazar M, et al. MicroRNAs in prostate cancer liquid biopsies: early detection, prognosis, and treatment monitoring. Cells. 2026;15:83. https:\/\/doi.org\/10.3390\/cells15010083.","journal-title":"Cells"},{"key":"3424_CR77","doi-asserted-by":"publisher","first-page":"BSR20211972","DOI":"10.1042\/BSR20211972","volume":"42","author":"MYC Stafford","year":"2022","unstructured":"Stafford MYC, Willoughby CE, Walsh CP, McKenna DJ. Prognostic value of miR-21 for prostate cancer: a systematic review and meta-analysis. Biosci Rep. 2022;42:BSR20211972. https:\/\/doi.org\/10.1042\/BSR20211972.","journal-title":"Biosci Rep"},{"key":"3424_CR78","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3390\/bios14120599","volume":"14","author":"S-T Pang","year":"2024","unstructured":"Pang S-T, Chiou Y-E, Lim J, Zhang Y-C, Zeng W-Z, Ong TA, et al. Urinary MicroRNA-21 for prostate cancer detection using a silver nanoparticle sensor: a promising diagnostic tool. Biosensors. 2024;14:599\u2013611. https:\/\/doi.org\/10.3390\/bios14120599.","journal-title":"Biosensors"},{"key":"3424_CR79","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1002\/pros.23376","volume":"77","author":"Y Xu","year":"2017","unstructured":"Xu Y, Qin S, An T, Tang Y, Huang Y, Zheng L. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method. Prostate. 2017;77:1167\u201375. https:\/\/doi.org\/10.1002\/pros.23376.","journal-title":"Prostate"},{"key":"3424_CR80","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.21037\/tau-20-421","volume":"10","author":"K Matsuzaki","year":"2021","unstructured":"Matsuzaki K, Fujita K, Tomiyama E, Hatano K, Hayashi Y, Wang C, et al. MiR-30b-3p and miR-126-3p of urinary extracellular vesicles could be new biomarkers for prostate cancer. Transl Androl Urol. 2021;10:1918\u201327. https:\/\/doi.org\/10.21037\/tau-20-421.","journal-title":"Transl Androl Urol"},{"key":"3424_CR81","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3390\/ijms20051154","volume":"20","author":"L Moya","year":"2019","unstructured":"Moya L, Meijer J, Schubert S, Matin F, Batra J. Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 expression as biomarker for prostate cancer diagnosis. Int J Mol Sci. 2019;20:1154. https:\/\/doi.org\/10.3390\/ijms20051154.","journal-title":"Int J Mol Sci"},{"key":"3424_CR82","doi-asserted-by":"publisher","first-page":"102294","DOI":"10.1016\/j.clgc.2024.102294","volume":"23","author":"R Osiecki","year":"2025","unstructured":"Osiecki R, Pop\u0142awski P, Sys D, Bogus\u0142awska J, Bia\u0142as A, Zawadzki M, et al. CIRCULATING miR-1-3p, miR-96-5p, miR-148a-3p, and miR-375-3p Support Differentiation Between Prostate Cancer and Benign Prostate Lesions. Clin Genitourin Cancer. 2025;23:102294. https:\/\/doi.org\/10.1016\/j.clgc.2024.102294.","journal-title":"Clin Genitourin Cancer"},{"key":"3424_CR83","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/pros.23295","volume":"77","author":"L Foj","year":"2017","unstructured":"Foj L, Ferrer F, Serra M, Ar\u00e9valo A, Gavagnach M, Gim\u00e9nez N, et al. Exosomal and non-exosomal urinary miRNAs in prostate cancer detection and prognosis: urinary miRNAs in prostate cancer. Prostate. 2017;77:573\u201383. https:\/\/doi.org\/10.1002\/pros.23295.","journal-title":"Prostate"},{"key":"3424_CR84","doi-asserted-by":"publisher","first-page":"102582","DOI":"10.1016\/j.tranon.2025.102582","volume":"63","author":"Y Panahi","year":"2026","unstructured":"Panahi Y, Avci CB, Ghafarlu A, Nourazarian A. Multimodal urinary biomarker panel achieves superior prostate cancer detection accuracy and reduces unnecessary biopsies. Transl Oncol. 2026;63:102582. https:\/\/doi.org\/10.1016\/j.tranon.2025.102582.","journal-title":"Transl Oncol"},{"key":"3424_CR85","doi-asserted-by":"publisher","first-page":"105895","DOI":"10.1016\/j.ebiom.2025.105895","volume":"119","author":"M Yuan","year":"2025","unstructured":"Yuan M, Moschovas MC, Joshi K, Sanada Y, Perera RA, Lee B, et al. A sensitive and specific non-invasive urine biomarker panel for prostate cancer detection. EBioMedicine. 2025;119:105895. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105895.","journal-title":"EBioMedicine"},{"key":"3424_CR86","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.3390\/cancers17233815","volume":"17","author":"Y-C Lin","year":"2025","unstructured":"Lin Y-C, Chen C-H, Lee M-S, Lee C-F, Hsiao P-W, Huang H-P, et al. Metabolomics-based liquid biopsy for predicting clinically significant prostate cancer. Cancers. 2025;17:3815. https:\/\/doi.org\/10.3390\/cancers17233815.","journal-title":"Cancers"},{"key":"3424_CR87","doi-asserted-by":"publisher","first-page":"150","DOI":"10.22465\/juo.244800260013","volume":"22","author":"VN Pavlov","year":"2024","unstructured":"Pavlov VN, Urmantsev MF, Bakeev MR, Akinyemi OS. The integral role and clinical significance of metabolic profiling in prostate cancer: a narrative review. J Urol Oncol. 2024;22:150\u20136. https:\/\/doi.org\/10.22465\/juo.244800260013.","journal-title":"J Urol Oncol"},{"key":"3424_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03312-x","author":"H Fuller","year":"2026","unstructured":"Fuller H, Agasaro OP, Guevara JM, Darst BF. Pre-diagnostic circulating untargeted metabolomics and risk of overall and clinically significant prostate cancer: a systematic review and meta-analysis. Br J Cancer. 2026. https:\/\/doi.org\/10.1038\/s41416-025-03312-x.","journal-title":"Br J Cancer"},{"key":"3424_CR89","doi-asserted-by":"publisher","first-page":"730638","DOI":"10.3389\/fonc.2021.730638","volume":"11","author":"B Xu","year":"2021","unstructured":"Xu B, Chen Y, Chen X, Gan L, Zhang Y, Feng J, et al. Metabolomics profiling discriminates prostate cancer from benign prostatic hyperplasia within the prostate-specific antigen gray zone. Front Oncol. 2021;11:730638. https:\/\/doi.org\/10.3389\/fonc.2021.730638.","journal-title":"Front Oncol"},{"key":"3424_CR90","doi-asserted-by":"publisher","first-page":"1691767","DOI":"10.3389\/fonc.2025.1691767","volume":"15","author":"Y Shen","year":"2025","unstructured":"Shen Y, Liu B, Zhou Y, Lv J, Zhang X, Yang C, et al. Serum metabolites with diagnostic potential in prostate cancer and the inhibitory effects of alpha-Tocomonoenol on prostate cancer cells. Front Oncol. 2025;15:1691767. https:\/\/doi.org\/10.3389\/fonc.2025.1691767.","journal-title":"Front Oncol"},{"key":"3424_CR91","doi-asserted-by":"publisher","first-page":"2411871","DOI":"10.1002\/smll.202411871","volume":"21","author":"Y Su","year":"2025","unstructured":"Su Y, Peng Z, Wang Y, Yang S, Xu X, Liu W, et al. Metabolites in serum small extracellular vesicles instead of small extracellular vesicles-depleted serum have better diagnostic value for cancers at early stage. Small. 2025;21:2411871. https:\/\/doi.org\/10.1002\/smll.202411871.","journal-title":"Small"},{"key":"3424_CR92","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.21037\/tau-2025-592","volume":"14","author":"J Panach-Navarrete","year":"2025","unstructured":"Panach-Navarrete J, Gonz\u00e1lez-Marrachelli V, Morales-Tatay JM, Garc\u00eda-Morata F, Sales-Maicas M\u00c1, Monle\u00f3n-Salvado D, et al. Urine metabolic analysis as a non-invasive method to predict biochemical recurrence in prostate cancer. Transl Androl Urol. 2025;14:3708\u201317. https:\/\/doi.org\/10.21037\/tau-2025-592.","journal-title":"Transl Androl Urol"},{"key":"3424_CR93","doi-asserted-by":"publisher","first-page":"128660","DOI":"10.1016\/j.talanta.2025.128660","volume":"297","author":"G Alasiri","year":"2026","unstructured":"Alasiri G, Alaseem AM, El-Wekil MM, Hamdy AK, Ali A-MBH. Ratiometric fluorometric detection of urinary sarcosine via GSH@Hg\/carbon dots\/sarcosine oxidase sensing platform: a non-invasive approach for prostate cancer diagnosis. Talanta. 2026;297:128660. https:\/\/doi.org\/10.1016\/j.talanta.2025.128660.","journal-title":"Talanta"},{"key":"3424_CR94","doi-asserted-by":"publisher","first-page":"13893","DOI":"10.3390\/ijms140713893","volume":"14","author":"N Cernei","year":"2013","unstructured":"Cernei N, Heger Z, Gumulec J, Zitka O, Masarik M, Babula P, et al. Sarcosine as a potential prostate cancer biomarker\u2014a review. Int J Mol Sci. 2013;14:13893\u2013908. https:\/\/doi.org\/10.3390\/ijms140713893.","journal-title":"Int J Mol Sci"},{"key":"3424_CR95","doi-asserted-by":"publisher","first-page":"376","DOI":"10.5534\/wjmh.230344","volume":"43","author":"C-H Chen","year":"2025","unstructured":"Chen C-H, Huang H-P, Chang K-H, Lee M-S, Lee C-F, Lin C-Y, et al. Predicting clinically significant prostate cancer using urine metabolomics via liquid chromatography mass spectrometry. World J Mens Health. 2025;43:376\u201386. https:\/\/doi.org\/10.5534\/wjmh.230344.","journal-title":"World J Mens Health"},{"key":"3424_CR96","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/pros.24229","volume":"81","author":"C Yu","year":"2021","unstructured":"Yu C, Niu L, Li L, Li T, Duan L, He Z, et al. Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis. Prostate. 2021;81:1320\u20138. https:\/\/doi.org\/10.1002\/pros.24229.","journal-title":"Prostate"},{"key":"3424_CR97","doi-asserted-by":"publisher","first-page":"117845","DOI":"10.1016\/j.cca.2024.117845","volume":"556","author":"T Ding","year":"2024","unstructured":"Ding T, He W, Yan H, Wei Z, Zeng X, Hao X. Metabolic profiling in tissues and urine of patients with prostatic lesions and the diagnostic value of urine extracellular vesicles metabolites in prostate cancer. Clin Chim Acta. 2024;556:117845. https:\/\/doi.org\/10.1016\/j.cca.2024.117845.","journal-title":"Clin Chim Acta"},{"key":"3424_CR98","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2016.10.011","volume":"70","author":"T Skotland","year":"2017","unstructured":"Skotland T, Ekroos K, Kauhanen D, Simolin H, Seierstad T, Berge V, et al. Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers. Eur J Cancer. 2017;70:122\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2016.10.011.","journal-title":"Eur J Cancer"},{"key":"3424_CR99","doi-asserted-by":"publisher","first-page":"1470442","DOI":"10.1080\/20013078.2018.1470442","volume":"7","author":"M Clos-Garcia","year":"2018","unstructured":"Clos-Garcia M, Loizaga-Iriarte A, Zu\u00f1iga-Garcia P, S\u00e1nchez-Mosquera P, Rosa Cortazar A, Gonz\u00e1lez E, et al. Metabolic alterations in urine extracellular vesicles are associated to prostate cancer pathogenesis and progression. J Extracell Vesicles. 2018;7:1470442. https:\/\/doi.org\/10.1080\/20013078.2018.1470442.","journal-title":"J Extracell Vesicles"},{"key":"3424_CR100","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1021\/acssensors.5c03331","volume":"11","author":"Y Cheng","year":"2026","unstructured":"Cheng Y, Bi X, Liu B, Chen Z, Lin LL, Wang Y, et al. Molecule-level interpretable SERS diagnosis of prostate cancer via prostatic fluid metabolites and extracellular vesicles. ACS Sens. 2026;11:1214\u201327. https:\/\/doi.org\/10.1021\/acssensors.5c03331.","journal-title":"ACS Sens"},{"key":"3424_CR101","doi-asserted-by":"publisher","unstructured":"Peng Z, Wang Y, Wu X, Yang S, Du X, Xu X, et al. Identifying high gleason score prostate cancer by prostate fluid metabolic fingerprint-based multi-modal recognition. Small Methods. 2024;2301684. https:\/\/doi.org\/10.1002\/smtd.202301684.","DOI":"10.1002\/smtd.202301684"},{"key":"3424_CR102","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/JU.0000000000004437","volume":"213","author":"A Lazarovich","year":"2025","unstructured":"Lazarovich A, Vigneswaran H, Palsdottir T, Eklund M, Discacciati A, Nordstr\u00f6m T, et al. A comparison of Stockholm3, serum biomarkers, and risk calculators to predict prostate cancer in a racially and ethnically diverse cohort: evaluation of the Stockholm3 multiethnic SEPTA trial. J Urol. 2025;213:590\u20139. https:\/\/doi.org\/10.1097\/JU.0000000000004437.","journal-title":"J Urol"},{"key":"3424_CR103","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.eururo.2018.06.022","volume":"74","author":"H Gr\u00f6nberg","year":"2018","unstructured":"Gr\u00f6nberg H, Eklund M, Picker W, Aly M, J\u00e4derling F, Adolfsson J, et al. Prostate cancer diagnostics using a combination of the Stockholm3 blood test and multiparametric magnetic resonance imaging. Eur Urol. 2018;74:722\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2018.06.022.","journal-title":"Eur Urol"},{"key":"3424_CR104","doi-asserted-by":"publisher","first-page":"e180219","DOI":"10.1001\/jamanetworkopen.2018.0219","volume":"1","author":"L Boesen","year":"2018","unstructured":"Boesen L, N\u00f8rgaard N, L\u00f8gager V, Balslev I, Bisbjerg R, Thestrup K-C, et al. Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study. JAMA Netw Open. 2018;1:e180219. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.0219.","journal-title":"JAMA Netw Open"},{"key":"3424_CR105","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1016\/j.ejrad.2016.10.009","volume":"85","author":"A Stanzione","year":"2016","unstructured":"Stanzione A, Imbriaco M, Cocozza S, Fusco F, Rusconi G, Nappi C, et al. Biparametric 3T Magnetic Resonance Imaging for prostatic cancer detection in a biopsy-na\u00efve patient population: a further improvement of PI-RADS v2? Eur J Radiol. 2016;85:2269\u201374. https:\/\/doi.org\/10.1016\/j.ejrad.2016.10.009.","journal-title":"Eur J Radiol"},{"key":"3424_CR106","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1148\/radiol.2017170129","volume":"285","author":"CK Kuhl","year":"2017","unstructured":"Kuhl CK, Bruhn R, Kr\u00e4mer N, Nebelung S, Heidenreich A, Schrading S. Abbreviated Biparametric Prostate MR Imaging in Men with Elevated Prostate-specific Antigen. Radiology. 2017;285:493\u2013505. https:\/\/doi.org\/10.1148\/radiol.2017170129.","journal-title":"Radiology"},{"key":"3424_CR107","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ca.21006","volume":"23","author":"YK Mariappan","year":"2010","unstructured":"Mariappan YK, Glaser KJ, Ehman RL. Magnetic resonance elastography: A review. Clin Anat. 2010;23:497\u2013511. https:\/\/doi.org\/10.1002\/ca.21006.","journal-title":"Clin Anat"},{"key":"3424_CR108","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.3390\/diagnostics15202603","volume":"15","author":"S Po\u00e7an","year":"2025","unstructured":"Po\u00e7an S, Karaka\u015f L. Lesion Stiffness Measured by Magnetic Resonance Elastography: A Novel Biomarker for Differentiating Benign, Premalignant and Malignant Prostate Lesions. Diagnostics. 2025;15:2603. https:\/\/doi.org\/10.3390\/diagnostics15202603.","journal-title":"Diagnostics"},{"key":"3424_CR109","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.3390\/cancers16203494","volume":"16","author":"SH Kim","year":"2024","unstructured":"Kim SH, Kim JY, Hwang MJ. Magnetic Resonance Elastography for the Detection and Classification of Prostate Cancer. Cancers. 2024;16:3494. https:\/\/doi.org\/10.3390\/cancers16203494.","journal-title":"Cancers"},{"key":"3424_CR110","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1038\/s41598-024-54341-0","volume":"14","author":"HJ Lee","year":"2024","unstructured":"Lee HJ, Cho SB, Lee JK, Kim JS, Oh CH, Kim HJ, et al. The feasibility of MR elastography with transpelvic vibration for localization of focal prostate lesion. Sci Rep. 2024;14:3864. https:\/\/doi.org\/10.1038\/s41598-024-54341-0.","journal-title":"Sci Rep"},{"key":"3424_CR111","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1148\/radiol.2021201852","volume":"299","author":"M Li","year":"2021","unstructured":"Li M, Guo J, Hu P, Jiang H, Chen J, Hu J, et al. Tomoelastography Based on Multifrequency MR Elastography for Prostate Cancer Detection: Comparison with Multiparametric MRI. Radiology. 2021;299:362\u201370. https:\/\/doi.org\/10.1148\/radiol.2021201852.","journal-title":"Radiology"},{"key":"3424_CR112","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3389\/fonc.2020.00161","volume":"10","author":"L Consolino","year":"2020","unstructured":"Consolino L, Anemone A, Capozza M, Carella A, Irrera P, Corrado A, et al. Non-invasive Investigation of Tumor Metabolism and Acidosis by MRI-CEST Imaging. Front Oncol. 2020;10:161. https:\/\/doi.org\/10.3389\/fonc.2020.00161.","journal-title":"Front Oncol"},{"key":"3424_CR113","doi-asserted-by":"publisher","first-page":"1780850","DOI":"10.3389\/fonc.2026.1780850","volume":"16","author":"J Feng","year":"2026","unstructured":"Feng J, Wang J, Wang J, Chen X, Xu M, Wang H. Association between amide proton transfer-weighted imaging biomarkers and Gleason score in prostate cancer: a study on differential diagnosis from benign prostatic hyperplasia. Front Oncol. 2026;16:1780850. https:\/\/doi.org\/10.3389\/fonc.2026.1780850.","journal-title":"Front Oncol"},{"key":"3424_CR114","doi-asserted-by":"publisher","first-page":"9036","DOI":"10.21037\/qims-24-1121","volume":"14","author":"Y Ye","year":"2024","unstructured":"Ye Y, Gong Z, Song Y, Yv L, Liu Z, Ying H, et al. Added value of amide proton transfer-weighted magnetic resonance imaging to Prostate Imaging Reporting and Data System version 2.1 in differentiating clinically significant prostate cancer. Quant Imaging Med Surg. 2024;14:9036\u201348. . https:\/\/doi.org\/10.21037\/qims-24-1121","journal-title":"Quant Imaging Med Surg"},{"key":"3424_CR115","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-025-05373-1","author":"X Cheng","year":"2026","unstructured":"Cheng X, Xu J, Yao J, Song B. MR-based techniques for imaging prostate cancer metabolism: current status and future perspectives. Abdom Radiol (NY). 2026. Epub ahead of print. https:\/\/doi.org\/10.1007\/s00261-025-05373-1","journal-title":"Abdom Radiol NY"},{"key":"3424_CR116","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00345-020-03193-0","volume":"39","author":"J-M Correas","year":"2021","unstructured":"Correas J-M, Halpern EJ, Barr RG, Ghai S, Walz J, Bodard S, et al. Advanced ultrasound in the diagnosis of prostate cancer. World J Urol. 2021;39:661\u201376. https:\/\/doi.org\/10.1007\/s00345-020-03193-0.","journal-title":"World J Urol"},{"key":"3424_CR117","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2025.3579","volume":"333","author":"A Kinnaird","year":"2025","unstructured":"Kinnaird A, Luger F, Cash H, Ghai S, Urdaneta-Salegui LF, Pavlovich CP, et al. Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial. JAMA. 2025;333:1679. https:\/\/doi.org\/10.1001\/jama.2025.3579.","journal-title":"JAMA"},{"key":"3424_CR118","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1148\/radiol.212163","volume":"305","author":"S Ghai","year":"2022","unstructured":"Ghai S, Perlis N, Atallah C, Jokhu S, Corr K, Lajkosz K, et al. Comparison of Micro-US and Multiparametric MRI for Prostate Cancer Detection in Biopsy-Naive Men. Radiology. 2022;305:390\u20138. https:\/\/doi.org\/10.1148\/radiol.212163.","journal-title":"Radiology"},{"key":"3424_CR119","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1053\/j.semnuclmed.2023.10.002","volume":"54","author":"M Caracciolo","year":"2024","unstructured":"Caracciolo M, Castello A, Lopci E. PSMA PET\/CT Versus mpMRI for the Detection of Clinically Significant Prostate Cancer: An Updated Overview. Semin Nucl Med. 2024;54:30\u20138. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.10.002.","journal-title":"Semin Nucl Med"},{"key":"3424_CR120","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466\u201386. https:\/\/doi.org\/10.1007\/s00259-022-06089-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3424_CR121","doi-asserted-by":"publisher","first-page":"15525","DOI":"10.1038\/s41598-024-65452-z","volume":"14","author":"Y Fu","year":"2024","unstructured":"Fu Y, Zhao M, Chen J, Wen Q, Chen B. Enhancing prostate cancer diagnosis and reducing unnecessary biopsies with [18F]DCFPyL PET\/CT imaging in PI-RADS 3\/4 patients. Sci Rep. 2024;14:15525. https:\/\/doi.org\/10.1038\/s41598-024-65452-z.","journal-title":"Sci Rep"},{"key":"3424_CR122","doi-asserted-by":"publisher","first-page":"e231879","DOI":"10.1148\/radiol.231879","volume":"311","author":"BM Priv\u00e9","year":"2024","unstructured":"Priv\u00e9 BM, Isra\u00ebl B, Janssen MJR, Van Der Leest MMG, De Rooij M, Van Ipenburg JA, et al. Multiparametric MRI and18F-PSMA-1007 PET\/CT for the Detection of Clinically Significant Prostate Cancer. Radiology. 2024;311:e231879. . https:\/\/doi.org\/10.1148\/radiol.231879","journal-title":"Radiology"},{"key":"3424_CR123","doi-asserted-by":"publisher","first-page":"e20755","DOI":"10.1097\/MD.0000000000020755","volume":"99","author":"L Wang","year":"2020","unstructured":"Wang L, Yu F, Yang L, Zang S, Xue H, Yin X, et al. 68Ga-PSMA-11 PET\/CT combining ADC value of MRI in the diagnosis of naive prostate cancer: Perspective of radiologist. Med (Baltim). 2020;99:e20755. https:\/\/doi.org\/10.1097\/MD.0000000000020755.","journal-title":"Med (Baltim)"},{"key":"3424_CR124","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","volume":"80","author":"L Emmett","year":"2021","unstructured":"Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol. 2021;80:682\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.002.","journal-title":"Eur Urol"},{"key":"3424_CR125","doi-asserted-by":"publisher","first-page":"1216894","DOI":"10.3389\/fonc.2023.1216894","volume":"13","author":"R Huang","year":"2023","unstructured":"Huang R, Li Y, Wu H, Liu B, Zhang X, Zhang Z. 68Ga-PSMA-11 PET\/CT versus 68Ga-PSMA-11 PET\/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis. Front Oncol. 2023;13:1216894. https:\/\/doi.org\/10.3389\/fonc.2023.1216894.","journal-title":"Front Oncol"},{"key":"3424_CR126","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1053\/j.semnuclmed.2023.08.001","volume":"54","author":"MCM Gammel","year":"2024","unstructured":"Gammel MCM, Solari EL, Eiber M, Rauscher I, Nekolla SG. A Clinical Role of PET-MRI in Prostate Cancer? Semin Nucl Med. 2024;54:132\u201340. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.08.001.","journal-title":"Semin Nucl Med"},{"key":"3424_CR127","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/JU.0000000000003680","volume":"210","author":"W Tang","year":"2023","unstructured":"Tang W, Tang Y, Qi L, Zhang Y, Tang G, Gao X, et al. Benign Prostatic Hyperplasia\u2013Related False-Positive of Prostate-Specific Membrane Antigen\u2013Positron Emission Tomography in the Diagnosis of Prostate Cancer: The Achilles\u2019 Heel of Biopsy-Free Radical Prostatectomy? J Urol. 2023;210:845\u201355. https:\/\/doi.org\/10.1097\/JU.0000000000003680.","journal-title":"J Urol"},{"key":"3424_CR128","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00432-025-06184-z","volume":"151","author":"Z Shen","year":"2025","unstructured":"Shen Z, Li Z, Li Y, Tang X, Lu J, Chen L, et al. PSMA PET\/CT for prostate cancer diagnosis: current applications and future directions. J Cancer Res Clin Oncol. 2025;151:155. https:\/\/doi.org\/10.1007\/s00432-025-06184-z.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3424_CR129","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1007\/s00261-021-03254-x","volume":"47","author":"KJ Lafata","year":"2021","unstructured":"Lafata KJ, Wang Y, Konkel B, Yin F-F, Bashir MR. Radiomics: a primer on high-throughput image phenotyping. Abdom Radiol. 2021;47:2986\u20133002. https:\/\/doi.org\/10.1007\/s00261-021-03254-x.","journal-title":"Abdom Radiol"},{"key":"3424_CR130","doi-asserted-by":"publisher","first-page":"158e17","DOI":"10.1016\/j.urolonc.2024.01.021","volume":"42","author":"C Yang","year":"2024","unstructured":"Yang C, Li B, Luan Y, Wang S, Bian Y, Zhang J, et al. Deep learning model for the detection of prostate cancer and classification of clinically significant disease using multiparametric MRI in comparison to PI-RADs score. Urol Oncol Semin Orig Investig. 2024;42:158e17. https:\/\/doi.org\/10.1016\/j.urolonc.2024.01.021.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"3424_CR131","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/jmri.27692","volume":"54","author":"SJ Hectors","year":"2021","unstructured":"Hectors SJ, Chen C, Chen J, Wang J, Gordon S, Yu M, et al. Magnetic Resonance Imaging Radiomics-Based Machine Learning Prediction of Clinically Significant Prostate Cancer in Equivocal PI\u2010RADS 3 Lesions. J Magn Reson Imaging. 2021;54:1466\u201373. https:\/\/doi.org\/10.1002\/jmri.27692.","journal-title":"J Magn Reson Imaging"},{"key":"3424_CR132","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12880-023-01002-9","volume":"23","author":"P Jin","year":"2023","unstructured":"Jin P, Shen J, Yang L, Zhang J, Shen A, Bao J, et al. Machine learning-based radiomics model to predict benign and malignant PI-RADS v2.1 category 3 lesions: a retrospective multi-center study. BMC Med Imaging. 2023;23:47. https:\/\/doi.org\/10.1186\/s12880-023-01002-9.","journal-title":"BMC Med Imaging"},{"key":"3424_CR133","doi-asserted-by":"publisher","first-page":"e232635","DOI":"10.1148\/radiol.232635","volume":"312","author":"JC Cai","year":"2024","unstructured":"Cai JC, Nakai H, Kuanar S, Froemming AT, Bolan CW, Kawashima A, et al. Fully Automated Deep Learning Model to Detect Clinically Significant Prostate Cancer at MRI. Radiology. 2024;312:e232635. https:\/\/doi.org\/10.1148\/radiol.232635.","journal-title":"Radiology"},{"issue":"6","key":"3424_CR134","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1016\/j.acra.2023.12.042","volume":"31","author":"Z Kang","year":"2024","unstructured":"Kang Z, Xiao E, Li Z, Wang L. Deep Learning Based on ResNet-18 for Classification of Prostate Imaging-Reporting and Data System Category 3 Lesions. Acad Radiol. 2024;31(6):2412\u201323. . https:\/\/doi.org\/10.1016\/j.acra.2023.12.042","journal-title":"Acad Radiol"},{"key":"3424_CR135","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1007\/s00330-025-11865-x","volume":"36","author":"PM Johnson","year":"2025","unstructured":"Johnson PM, Tong A, Ginocchio L, Del Hoyo JL, Smereka P, Harmon SA, et al. External evaluation of an open-source deep learning model for prostate cancer detection on bi-parametric MRI. Eur Radiol. 2025;36:1084\u201392. https:\/\/doi.org\/10.1007\/s00330-025-11865-x.","journal-title":"Eur Radiol"},{"key":"3424_CR136","doi-asserted-by":"publisher","first-page":"e222276","DOI":"10.1148\/radiol.222276","volume":"307","author":"CA Hamm","year":"2023","unstructured":"Hamm CA, Baumg\u00e4rtner GL, Biessmann F, Beetz NL, Hartenstein A, Savic LJ, et al. Interactive Explainable Deep Learning Model Informs Prostate Cancer Diagnosis at MRI. Radiology. 2023;307:e222276. https:\/\/doi.org\/10.1148\/radiol.222276.","journal-title":"Radiology"},{"key":"3424_CR137","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S1470-2045(24)00220-1","volume":"25","author":"A Saha","year":"2024","unstructured":"Saha A, Bosma JS, Twilt JJ, Van Ginneken B, Bjartell A, Padhani AR, et al. Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study. Lancet Oncol. 2024;25:879\u201387. https:\/\/doi.org\/10.1016\/S1470-2045(24)00220-1.","journal-title":"Lancet Oncol"},{"key":"3424_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.12.009","author":"J Walz","year":"2025","unstructured":"Walz J, Attard G, Bjartell A, Blanchard P, Castro E, Comp\u00e9rat E, et al. Local and locoregional prostate cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025. https:\/\/doi.org\/10.1016\/j.annonc.2025.12.009. S0923753425063306.","journal-title":"Ann Oncol"},{"key":"3424_CR139","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.euo.2020.08.014","volume":"4","author":"UG Falagario","year":"2021","unstructured":"Falagario UG, Jambor I, Lantz A, Ettala O, Stabile A, Taimen P, et al. Combined use of prostate-specific antigen density and magnetic resonance imaging for prostate biopsy decision planning: a retrospective multi-institutional study using the prostate magnetic resonance imaging outcome database (PROMOD). Eur Urol Oncol. 2021;4:971\u20139. https:\/\/doi.org\/10.1016\/j.euo.2020.08.014.","journal-title":"Eur Urol Oncol"},{"key":"3424_CR140","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/bju.13465","volume":"119","author":"S Washino","year":"2017","unstructured":"Washino S, Okochi T, Saito K, Konishi T, Hirai M, Kobayashi Y, et al. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate\u2010specific antigen (PSA) density predicts biopsy outcome in prostate biopsy na\u00efve patients. BJU Int. 2017;119:225\u201333. . https:\/\/doi.org\/10.1111\/bju.13465","journal-title":"BJU Int"},{"key":"3424_CR141","doi-asserted-by":"publisher","unstructured":"Durmaz S, Wu S-CJ, Lee K-L, Shakur A, Caglic I, Barrett T. The effects of prostate volume and PI-RADS category on optimal PSA-density thresholds for biopsy decision-making. Eur Radiol. 2026;1\u201310. https:\/\/doi.org\/10.1007\/s00330-025-12272-y.","DOI":"10.1007\/s00330-025-12272-y"},{"key":"3424_CR142","doi-asserted-by":"publisher","first-page":"2446695","DOI":"10.1080\/07853890.2024.2446695","volume":"57","author":"P Jin","year":"2025","unstructured":"Jin P, Wang X, Ding Z, Yang L, Xu C, Wang X, et al. Development and validation of risk-stratified biopsy decision pathways incorporating MRI and PSA-derived indicators. Ann Med. 2025;57:2446695. https:\/\/doi.org\/10.1080\/07853890.2024.2446695.","journal-title":"Ann Med"},{"key":"3424_CR143","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/JU.0000000000003603","volume":"210","author":"K Yim","year":"2023","unstructured":"Yim K, Ma C, Carlsson S, Lilja H, Mucci L, Penney K, et al. Free PSA and clinically significant and fatal prostate cancer in the PLCO screening trial. J Urol. 2023;210:630\u20138. https:\/\/doi.org\/10.1097\/JU.0000000000003603.","journal-title":"J Urol"},{"key":"3424_CR144","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/iju.70024","volume":"32","author":"Y Sekine","year":"2025","unstructured":"Sekine Y, Fujizuka Y, Nakazawa S, Tsuji Y, Ohtsu A, Miyazawa Y, et al. Utility of combining prostate health index and magnetic resonance imaging for the diagnosis of prostate cancer. Int J Urol. 2025;32:658\u201363. https:\/\/doi.org\/10.1111\/iju.70024.","journal-title":"Int J Urol"},{"key":"3424_CR145","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s00345-019-02889-2","volume":"38","author":"P-F Hsieh","year":"2020","unstructured":"Hsieh P-F, Li W-J, Lin W-C, Chang H, Chang C-H, Huang C-P, et al. Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population. World J Urol. 2020;38:1207\u201314. https:\/\/doi.org\/10.1007\/s00345-019-02889-2.","journal-title":"World J Urol"},{"key":"3424_CR146","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/JU.0000000000003450","volume":"210","author":"PK-F Chiu","year":"2023","unstructured":"Chiu PK-F, Leow JJ, Chiang C-H, Mok A, Zhang K, Hsieh P-F, et al. Prostate health index density outperforms prostate-specific antigen density in the diagnosis of clinically significant prostate cancer in equivocal magnetic resonance imaging of the prostate: a multicenter evaluation. J Urol. 2023;210:88\u201398. https:\/\/doi.org\/10.1097\/JU.0000000000003450.","journal-title":"J Urol"},{"key":"3424_CR147","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/bju.13762","volume":"120","author":"JJ Tosoian","year":"2017","unstructured":"Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, et al. Prostate health index density improves detection of clinically significant prostate cancer. BJU Int. 2017;120:793\u20138. https:\/\/doi.org\/10.1111\/bju.13762.","journal-title":"BJU Int"},{"key":"3424_CR148","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.5534\/wjmh.250169","volume":"43","author":"J Yu","year":"2026","unstructured":"Yu J, Chi SA, Kang M, Sung HH, Jeon HG, Jeong BC, et al. Enhancing risk stratification in equivocal prostate magnetic resonance imaging lesions: clinical utility of prostate health index and prostate health index density in prostate imaging\u2013reporting and data system 3. World J Mens Health. 2026;43:e86. https:\/\/doi.org\/10.5534\/wjmh.250169.","journal-title":"World J Mens Health"},{"key":"3424_CR149","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.euo.2019.08.015","volume":"3","author":"UG Falagario","year":"2020","unstructured":"Falagario UG, Martini A, Wajswol E, Treacy P-J, Ratnani P, Jambor I, et al. Avoiding unnecessary magnetic resonance imaging (MRI) and biopsies: negative and positive predictive value of MRI according to prostate-specific antigen density, 4Kscore and risk calculators. Eur Urol Oncol. 2020;3:700\u20134. https:\/\/doi.org\/10.1016\/j.euo.2019.08.015.","journal-title":"Eur Urol Oncol"},{"key":"3424_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/JU9.0000000000000134","volume":"2","author":"JC Wang","year":"2024","unstructured":"Wang JC, Vetter JM, Kim EH, Gross JT, Henning GM. The clinical impact of the 4Kscore test on prostate biopsy decision making in the setting of MRI. JU Open Plus. 2024;2:1\u20136. https:\/\/doi.org\/10.1097\/JU9.0000000000000134.","journal-title":"JU Open Plus"},{"key":"3424_CR151","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1200\/JCO.2022.40.6_suppl.031","volume":"40","author":"DR Nemirovsky","year":"2022","unstructured":"Nemirovsky DR, Reddy AG, McSweeney B, Klose C, Chen J, Atienza M, et al. Tailoring 4Kscore thresholds to multiparametric MRI results. J Clin Oncol. 2022;40:31\u201331. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.031.","journal-title":"J Clin Oncol"},{"key":"3424_CR152","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41391-023-00782-z","volume":"27","author":"S Guo","year":"2024","unstructured":"Guo S, Zhang J, Wang Y, Jiao J, Li Z, Cui C, et al. Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision. Prostate Cancer Prostatic Dis. 2024;27:288\u201393. https:\/\/doi.org\/10.1038\/s41391-023-00782-z.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3424_CR153","doi-asserted-by":"publisher","first-page":"27453","DOI":"10.1038\/s41598-025-12312-z","volume":"15","author":"W Hu","year":"2025","unstructured":"Hu W, Guo S, Meng X, Wang F, Ma S, Zhang C, et al. Development and validation of a visual nomogram for predicting clinically significant prostate cancer in negative mpMRI using 68Ga-PSMA PET\/CT. Sci Rep. 2025;15:27453. https:\/\/doi.org\/10.1038\/s41598-025-12312-z.","journal-title":"Sci Rep"},{"key":"3424_CR154","doi-asserted-by":"publisher","unstructured":"Wendler JJ, Bechstein J, Buckendahl J, Kruck S, Samtleben C, Liehr BU, et al. The value of micro-ultrasound for prostate cancer screening: a retrospective real-world feasibility study. Prostate Cancer Prostatic Dis. 2026;1\u20137. https:\/\/doi.org\/10.1038\/s41391-026-01075-x.","DOI":"10.1038\/s41391-026-01075-x"},{"key":"3424_CR155","doi-asserted-by":"publisher","first-page":"106144","DOI":"10.1016\/j.ijmedinf.2025.106144","volume":"206","author":"NS Domingues","year":"2026","unstructured":"Domingues NS. A hybrid decision support system using rule-based and AI methods: the OnCATs knowledge-based framework. Int J Med Inform. 2026;206:106144. https:\/\/doi.org\/10.1016\/j.ijmedinf.2025.106144","journal-title":"Int J Med Inf"},{"key":"3424_CR156","doi-asserted-by":"publisher","first-page":"e30430","DOI":"10.2196\/30430","volume":"7","author":"A Bandala-Jacques","year":"2021","unstructured":"Bandala-Jacques A, Castellanos Esquivel KD, P\u00e9rez-Hurtado F, Hern\u00e1ndez-Silva C, Reynoso-Nover\u00f3n N. Prostate cancer risk calculators for healthy populations: systematic review. JMIR Cancer. 2021;7:e30430. https:\/\/doi.org\/10.2196\/30430.","journal-title":"JMIR Cancer"},{"key":"3424_CR157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2022.04.010","volume":"41","author":"J Chandra Engel","year":"2022","unstructured":"Chandra Engel J, Palsdottir T, Ankerst D, Remmers S, Mortezavi A, Chellappa V, et al. External validation of the prostate biopsy collaborative group risk calculator and the rotterdam prostate cancer risk calculator in a swedish population-based screening cohort. Eur Urol Open Sci. 2022;41:1\u20137. https:\/\/doi.org\/10.1016\/j.euros.2022.04.010.","journal-title":"Eur Urol Open Sci"},{"key":"3424_CR158","doi-asserted-by":"publisher","first-page":"416e1","DOI":"10.1016\/j.urolonc.2016.04.004","volume":"34","author":"R Chen","year":"2016","unstructured":"Chen R, Xie L, Xue W, Ye Z, Ma L, Gao X, et al. Development and external multicenter validation of chinese prostate cancer consortium prostate cancer risk calculator for initial prostate biopsy. Urol Oncol Semin Orig Investig. 2016;34:416e1. https:\/\/doi.org\/10.1016\/j.urolonc.2016.04.004.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"3424_CR159","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.urology.2014.02.035","volume":"83","author":"DP Ankerst","year":"2014","unstructured":"Ankerst DP, Hoefler J, Bock S, Goodman PJ, Vickers A, Hernandez J, et al. Prostate cancer prevention trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology. 2014;83:1362\u20138. https:\/\/doi.org\/10.1016\/j.urology.2014.02.035.","journal-title":"Urology"},{"key":"3424_CR160","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.euf.2018.01.010","volume":"5","author":"DP Ankerst","year":"2019","unstructured":"Ankerst DP, Goros M, Tomlins SA, Patil D, Feng Z, Wei JT, et al. Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus. 2019;5:54\u201361. https:\/\/doi.org\/10.1016\/j.euf.2018.01.010.","journal-title":"Eur Urol Focus"},{"key":"3424_CR161","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2018.05.003","volume":"74","author":"DP Ankerst","year":"2018","unstructured":"Ankerst DP, Straubinger J, Selig K, Guerrios L, De Hoedt A, Hernandez J, et al. A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts. Eur Urol. 2018;74:197\u2013203. https:\/\/doi.org\/10.1016\/j.eururo.2018.05.003.","journal-title":"Eur Urol"},{"key":"3424_CR162","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12894-019-0553-6","volume":"19","author":"S Carbunaru","year":"2019","unstructured":"Carbunaru S, Nettey OS, Gogana P, Helenowski IB, Jovanovic B, Ruden M, et al. A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort. BMC Urol. 2019;19:121\u20139. https:\/\/doi.org\/10.1186\/s12894-019-0553-6.","journal-title":"BMC Urol"},{"key":"3424_CR163","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.ejca.2010.11.012","volume":"47","author":"HA Van Vugt","year":"2011","unstructured":"Van Vugt HA, Roobol MJ, Kranse R, M\u00e4\u00e4tt\u00e4nen L, Finne P, Hugosson J, et al. Prediction of prostate cancer in unscreened men: external validation of a risk calculator. Eur J Cancer. 2011;47:903\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2010.11.012.","journal-title":"Eur J Cancer"},{"key":"3424_CR164","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.eururo.2011.11.012","volume":"61","author":"MJ Roobol","year":"2012","unstructured":"Roobol MJ, Van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol. 2012;61:577\u201383. https:\/\/doi.org\/10.1016\/j.eururo.2011.11.012.","journal-title":"Eur Urol"},{"key":"3424_CR165","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/bju.13437","volume":"118","author":"RW Foley","year":"2016","unstructured":"Foley RW, Maweni RM, Gorman L, Murphy K, Lundon DJ, Durkan G, et al. European randomised study of screening for prostate cancer (ERSPC) risk calculators significantly outperform the prostate cancer prevention trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study. BJU Int. 2016;118:706\u201313. https:\/\/doi.org\/10.1111\/bju.13437.","journal-title":"BJU Int"},{"key":"3424_CR166","doi-asserted-by":"publisher","unstructured":"Courtney O\u2019Toole C, Boakye NF, Hannigan A, Jalali A. Clinical impact of MRI-based risk calculators for prostate cancer diagnosis: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2025;1\u201311. https:\/\/doi.org\/10.1038\/s41391-025-01014-2.","DOI":"10.1038\/s41391-025-01014-2"},{"key":"3424_CR167","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.eururo.2018.07.031","volume":"75","author":"AR Alberts","year":"2019","unstructured":"Alberts AR, Roobol MJ, Verbeek JFM, Schoots IG, Chiu PK, Osses DF, et al. Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the rotterdam european randomized study of screening for prostate cancer risk calculators. Eur Urol. 2019;75:310\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2018.07.031.","journal-title":"Eur Urol"},{"key":"3424_CR168","doi-asserted-by":"publisher","first-page":"1343999","DOI":"10.3389\/fonc.2024.1343999","volume":"14","author":"T Hermanns","year":"2024","unstructured":"Hermanns T, Wettstein MS, Kaufmann B, Lautenbach N, Kaufmann E, Saba K, et al. Development and Validation of a Contemporary Prostate Cancer Risk Calculator. Front Oncol. 2024;14:1343999. https:\/\/doi.org\/10.3389\/fonc.2024.1343999.","journal-title":"Front Oncol"},{"key":"3424_CR169","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1200\/JCO.24.00152","volume":"42","author":"HT Vigneswaran","year":"2024","unstructured":"Vigneswaran HT, Eklund M, Discacciati A, Nordstr\u00f6m T, Hubbard RA, Perlis N, et al. Stockholm3 in a multiethnic cohort for prostate cancer detection (SEPTA): a prospective multicentered trial. J Clin Oncol. 2024;42:3806\u201316. https:\/\/doi.org\/10.1200\/JCO.24.00152","journal-title":"J Clin Oncol"},{"key":"3424_CR170","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.euf.2024.07.009","volume":"11","author":"D Tilki","year":"2025","unstructured":"Tilki D, Rejek N, Nohe F, Haese A, Graefen M, Thederan I. External validation of Stockholm3 in a retrospective german clinical cohort. Eur Urol Focus. 2025;11:82\u20137. https:\/\/doi.org\/10.1016\/j.euf.2024.07.009.","journal-title":"Eur Urol Focus"},{"key":"3424_CR171","doi-asserted-by":"publisher","first-page":"e240078","DOI":"10.1148\/rycan.240078","volume":"7","author":"C Roest","year":"2025","unstructured":"Roest C, Kwee TC, de Jong IJ, Schoots IG, van Leeuwen P, Heijmink SWTPJ, et al. Development and validation of a deep learning model based on MRI and clinical characteristics to predict risk of prostate cancer progression. Radiol Imaging Cancer. 2025;7:e240078. https:\/\/doi.org\/10.1148\/rycan.240078.","journal-title":"Radiol Imaging Cancer"},{"key":"3424_CR172","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/bju.15122","volume":"126","author":"J Suh","year":"2020","unstructured":"Suh J, Yoo S, Park J, Cho SY, Cho MC, Son H, et al. Development and validation of an explainable artificial intelligence-based decision-supporting tool for prostate biopsy. BJU Int. 2020;126:694\u2013703. https:\/\/doi.org\/10.1111\/bju.15122.","journal-title":"BJU Int"},{"key":"3424_CR173","doi-asserted-by":"publisher","unstructured":"Roach M, Zhang J, Mohamad O, Van Der Wal D, Simko JP, DeVries S, et al. Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials. JCO Clin Cancer Inf. 2025;e2400284. https:\/\/doi.org\/10.1200\/CCI-24-00284.","DOI":"10.1200\/CCI-24-00284"},{"key":"3424_CR174","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1097\/RLI.0000000000001102","volume":"59","author":"C Roest","year":"2024","unstructured":"Roest C, Yakar D, Rener Sitar DI, Bosma JS, Rouw DB, Fransen SJ, et al. Multimodal AI combining clinical and imaging inputs improves prostate cancer detection. Invest Radiol. 2024;59:854\u201360. https:\/\/doi.org\/10.1097\/RLI.0000000000001102.","journal-title":"Invest Radiol"},{"key":"3424_CR175","doi-asserted-by":"publisher","first-page":"102625","DOI":"10.1016\/j.compmedimag.2025.102625","volume":"124","author":"O Bashkanov","year":"2025","unstructured":"Bashkanov O, Engelage L, Behnel N, Ehrlich P, Hansen C, Rak M. Multimodal data fusion with irregular PSA kinetics for automated prostate cancer grading. Comput Med Imaging Graph. 2025;124:102625. https:\/\/doi.org\/10.1016\/j.compmedimag.2025.102625.","journal-title":"Comput Med Imaging Graph"},{"key":"3424_CR176","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13014-024-02471-0","volume":"19","author":"DD Gunashekar","year":"2024","unstructured":"Gunashekar DD, Bielak L, Oerther B, Benndorf M, Nedelcu A, Hickey S, et al. Comparison of data fusion strategies for automated prostate lesion detection using mpMRI correlated with whole mount histology. Radiat Oncol. 2024;19:96\u2013105. https:\/\/doi.org\/10.1186\/s13014-024-02471-0.","journal-title":"Radiat Oncol"},{"key":"3424_CR177","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.3390\/curroncol31110530","volume":"31","author":"H Takeda","year":"2024","unstructured":"Takeda H, Akatsuka J, Kiriyama T, Toyama Y, Numata Y, Morikawa H, et al. Clinically significant prostate cancer prediction using multimodal deep learning with prostate-specific antigen restriction. Curr Oncol. 2024;31:7180\u20139. https:\/\/doi.org\/10.3390\/curroncol31110530.","journal-title":"Curr Oncol"},{"key":"3424_CR178","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1186\/s40001-025-03426-1","volume":"30","author":"W Xie","year":"2025","unstructured":"Xie W, Wu G, Qi X, Zhong L, Guo L, Tong M, et al. An innovative approach for predicting prostate cancer gleason grading: machine learning-based fusion of multimodal ultrasound, clinical and laboratory indicators. Eur J Med Res. 2025;30:1051. https:\/\/doi.org\/10.1186\/s40001-025-03426-1.","journal-title":"Eur J Med Res"},{"key":"3424_CR179","doi-asserted-by":"publisher","first-page":"1137322","DOI":"10.3389\/fendo.2023.1137322","volume":"14","author":"M Zhang","year":"2023","unstructured":"Zhang M, Liu Y, Yao J, Wang K, Tu J, Hu Z, et al. Value of machine learning-based transrectal multimodal ultrasound combined with PSA-related indicators in the diagnosis of clinically significant prostate cancer. Front Endocrinol. 2023;14:1137322. https:\/\/doi.org\/10.3389\/fendo.2023.1137322.","journal-title":"Front Endocrinol"},{"key":"3424_CR180","doi-asserted-by":"publisher","first-page":"e240050","DOI":"10.1148\/rycan.240050","volume":"6","author":"EC Yilmaz","year":"2024","unstructured":"Yilmaz EC, Harmon SA, Law YM, Huang EP, Belue MJ, Lin Y, et al. External validation of a previously developed deep learning\u2013based prostate lesion detection algorithm on paired external and In-house biparametric MRI scans. Radiol Imaging Cancer. 2024;6:e240050. https:\/\/doi.org\/10.1148\/rycan.240050.","journal-title":"Radiol Imaging Cancer"},{"key":"3424_CR181","doi-asserted-by":"publisher","first-page":"34038","DOI":"10.1038\/s41598-025-13824-4","volume":"15","author":"AN Zaheer","year":"2025","unstructured":"Zaheer AN, Farhan M, Min G, Alotaibi FA, Alnfiai MM. Attention-enhanced hybrid U-net for prostate cancer grading and explainability. Sci Rep. 2025;15:34038. https:\/\/doi.org\/10.1038\/s41598-025-13824-4.","journal-title":"Sci Rep"},{"key":"3424_CR182","doi-asserted-by":"publisher","first-page":"205520762513680","DOI":"10.1177\/20552076251368045","volume":"11","author":"K Agrawal","year":"2025","unstructured":"Agrawal K, El Shawi R, Ahmed N. eXplainable artificial intelligence-eval: a framework for comparative evaluation of explanation methods in healthcare. Digit Health. 2025;11:20552076251368045. https:\/\/doi.org\/10.1177\/20552076251368045.","journal-title":"Digit Health"},{"key":"3424_CR183","doi-asserted-by":"publisher","first-page":"1531866","DOI":"10.3389\/fendo.2025.1531866","volume":"16","author":"Y Ahamed","year":"2025","unstructured":"Ahamed Y, Hossain M, Baral S, Chen J, Sun W. The diagnostic value of prostate health index combined with soluble e-cadherin for prostate cancer. Front Endocrinol. 2025;16:1531866. https:\/\/doi.org\/10.3389\/fendo.2025.1531866.","journal-title":"Front Endocrinol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03424-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03424-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03424-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:37:35Z","timestamp":1791268655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03424-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":183,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["3424"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03424-1","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"22 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"305"}}